CRISPR touts new results as fresh questions surround 'off-the-shelf' CAR-T

An experimental "off-the-shelf" cell therapy for cancer helped eliminate or reduce disease in more than half of the lymphoma patients infused with higher doses in a clinical trial, a finding that the treatment's owner, CRISPR Therapeutics, says can match up with similar, rival drugs that are more logistically complex.